JP6383151B2 - 脳損傷治療用ｓｔｅｐ誘導ペプチド - Google Patents

脳損傷治療用ｓｔｅｐ誘導ペプチド Download PDF

Info

Publication number
JP6383151B2
JP6383151B2 JP2013529343A JP2013529343A JP6383151B2 JP 6383151 B2 JP6383151 B2 JP 6383151B2 JP 2013529343 A JP2013529343 A JP 2013529343A JP 2013529343 A JP2013529343 A JP 2013529343A JP 6383151 B2 JP6383151 B2 JP 6383151B2
Authority
JP
Japan
Prior art keywords
peptide according
domain
derived peptide
residue
numbering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013529343A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014505010A (ja
JP2014505010A5 (enExample
Inventor
ポール，スロジット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UNM Rainforest Innovations
Original Assignee
STC UNM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by STC UNM filed Critical STC UNM
Publication of JP2014505010A publication Critical patent/JP2014505010A/ja
Publication of JP2014505010A5 publication Critical patent/JP2014505010A5/ja
Application granted granted Critical
Publication of JP6383151B2 publication Critical patent/JP6383151B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2013529343A 2010-09-15 2011-09-15 脳損傷治療用ｓｔｅｐ誘導ペプチド Expired - Fee Related JP6383151B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38320810P 2010-09-15 2010-09-15
US61/383,208 2010-09-15
PCT/US2011/051827 WO2012037397A2 (en) 2010-09-15 2011-09-15 Step-derived peptide for brain injury treatment

Publications (3)

Publication Number Publication Date
JP2014505010A JP2014505010A (ja) 2014-02-27
JP2014505010A5 JP2014505010A5 (enExample) 2014-10-16
JP6383151B2 true JP6383151B2 (ja) 2018-08-29

Family

ID=45832252

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013529343A Expired - Fee Related JP6383151B2 (ja) 2010-09-15 2011-09-15 脳損傷治療用ｓｔｅｐ誘導ペプチド

Country Status (5)

Country Link
US (3) US9068172B2 (enExample)
EP (1) EP2616485A4 (enExample)
JP (1) JP6383151B2 (enExample)
CA (1) CA2811086C (enExample)
WO (1) WO2012037397A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2616485A4 (en) * 2010-09-15 2014-04-02 Stc Unm STEPPED DEVELOPED PEPTIDE FOR THE TREATMENT OF BRAIN INJURIES
GB201314610D0 (en) 2013-08-15 2013-10-02 Blueberry Therapeutics Ltd Compounds and their uses
WO2021155354A1 (en) * 2020-01-31 2021-08-05 Unm Rainforest Innovations Regulation of post-ischemic inflammatory response
RO135590A1 (ro) 2020-08-31 2022-03-30 Szedlacsek Ştefan Eugen Peptide de interferenţă ca inhibitori ai interacţiunilor legate de endocitoza receptorilor ampa

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015834A (en) 1992-10-20 2000-01-18 Toronto Neuroprotection Group In vivo treatment of mammalian cells with a cell membrane permeant calcium buffer
CA2494348C (en) 2002-08-01 2014-04-08 Yeda Research And Development Co. Ltd. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
US20050142630A1 (en) 2003-12-08 2005-06-30 Agy Therapeutics, Inc. Interaction of NMDA receptor with the protein tyrosine phosphatase step in psychotic disorders
AU2007226134A1 (en) 2006-03-16 2007-09-20 Mor Research Applications Ltd. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
US20090004112A1 (en) 2006-04-21 2009-01-01 The Trustees Of Columbia University In The City Of New York Methods for the treatment of neurodegenerative diseases using nmda receptor glycine site antagonists
KR100999043B1 (ko) * 2007-12-04 2010-12-09 한국생명공학연구원 융합 단백질을 사용하지 않는 인간 단백질 타이로신탈인산화 효소의 활성 도메인 대량 생산 방법
WO2009099563A2 (en) 2008-02-05 2009-08-13 Blanchette Rockefeller Neurosciences Institute Combination of a nmda receptor channel blocker and a pkc activator for treatment of alzheimer's disease
EP2616485A4 (en) * 2010-09-15 2014-04-02 Stc Unm STEPPED DEVELOPED PEPTIDE FOR THE TREATMENT OF BRAIN INJURIES

Also Published As

Publication number Publication date
WO2012037397A3 (en) 2012-06-28
US20150252339A1 (en) 2015-09-10
JP2014505010A (ja) 2014-02-27
US10087429B2 (en) 2018-10-02
EP2616485A2 (en) 2013-07-24
WO2012037397A2 (en) 2012-03-22
US10570381B2 (en) 2020-02-25
CA2811086A1 (en) 2012-03-22
US9068172B2 (en) 2015-06-30
US20190169583A1 (en) 2019-06-06
CA2811086C (en) 2020-07-21
EP2616485A4 (en) 2014-04-02
US20140170130A1 (en) 2014-06-19

Similar Documents

Publication Publication Date Title
Beurdeley et al. Otx2 binding to perineuronal nets persistently regulates plasticity in the mature visual cortex
Chen et al. PTEN: tumor suppressor and metabolic regulator
Wemmie et al. Acid-sensing ion channels in pain and disease
Pinkaew et al. Fortilin binds IRE1α and prevents ER stress from signaling apoptotic cell death
De Logu et al. Ion channel pharmacology for pain modulation
Schnizler et al. Protein kinase A anchoring via AKAP150 is essential for TRPV1 modulation by forskolin and prostaglandin E2 in mouse sensory neurons
Shirwany et al. AMPK: a cellular metabolic and redox sensor. A minireview
Sacktor Memory maintenance by PKMζ—an evolutionary perspective
US9107868B2 (en) Neuronal pain pathway
Zhang et al. Unfolded protein response as a therapeutic target in cardiovascular disease
Li et al. BDNF contributes to spinal long-term potentiation and mechanical hypersensitivity via Fyn-mediated phosphorylation of NMDA receptor GluN2B subunit at tyrosine 1472 in rats following spinal nerve ligation
Weeks et al. Roles and post‐translational regulation of cardiac class IIa histone deacetylase isoforms
US10570381B2 (en) STEP-derived peptide for brain injury treatment
JP6403240B2 (ja) シータデフェンシンによる炎症性プロテアーゼの遮断
JP2012524112A (ja) 統合失調症および双極性障害を治療するための組織カリクレイン
Palazzo et al. Nociception modulation by supraspinal group III metabotropic glutamate receptors
Lazarev et al. Factors affecting aggregate formation in cell models of Huntington’s disease and amyotrophic lateral sclerosis
Peng et al. Hydrogen sulfide upregulates acid-sensing ion channels via the MAPK-Erk1/2 signaling pathway
Albert et al. Neuroprotective and reparative effects of endoplasmic reticulum luminal proteins–mesencephalic astrocytederived neurotrophic factor and cerebral dopamine neurotrophic factor
US20250017926A1 (en) REGULATION OF eIF4E ACTIVITY FOR MIGRAINE THERAPY
Grueter et al. Group I mGluRs and long-term depression: potential roles in addiction?
Nury et al. Roles and potential therapeutic targets of the ubiquitin proteasome system in muscle wasting
CN101491538A (zh) 锂盐在制备治疗精神兴奋类药物成瘾的药物上的用途
Song et al. GSK-3β activation is required for ZIP-induced disruption of learned fear
Cruz-Torres Modifications to TRPM2 channel activity following global cerebral ischemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140304

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160314

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160516

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170309

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170316

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20170519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180517

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180803

R150 Certificate of patent or registration of utility model

Ref document number: 6383151

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees